psoriasis
Conditions
Interventions
Intervention group:MTX and PSORI-CM02 granules
Control group:MTX and granule placebos
Sponsors
Guangdong Provincial Hospital of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Patients who are definitely diagnosed with vulgaris psoriasis with mild to severe skin damage (10 < PASI < 40 or 10% < BSA < 40%); 2. Aged 18 to 60 years old male or female patient; 3. Informed consent.
Exclusion criteria
Exclusion criteria: 1. Arthrotype, pustule type, drip type, erythrodermic psoriasis; 2. Pregnancy, breastfeeding women, or a planned pregnancy within half a year; 3. The psychological measurement scale SAS standard division > 50 or SDS standard > 53, or the combination of other mental illness patients; 4. Vulgaris psoriasis patients with severe primary diseases involving respiratory system, circulatory system, digestive system, endocrine system and urinary system, etc,which can not be controlled by comment medicine.Vulgaris psoriasis patients with severe infection, hepatitis, tuberculosis, lymphocytic hyperplasia, abnormal hematopoietic system and tumor.Vulgaris psoriasis patients with severe water, electrolyte and acid-base balance disorders.Vulgaris psoriasis patients with primary or secondary immunodeficiency and hypersensitivity.Or the clinical test index is one of the following: the ALT or the AST is higher than 1.5 times the normal value limit; the creatinine(Cr) is higher than 1.5 times the normal value limit; anyone of the main blood indicators (white blood cells count, red blood cells count, hemoglobin, platelet count) is lower than normal lower limit;or patients with other abnormal laboratory tests that the researchers judged unfit to participate in the trial; 5. They are known to be allergic to drugs used in the study and those who are allergic to the drugs involved. 6. Participants in other clinical trials or other clinical trials in 12 weeks; 7. Treatment of Chinese medicine or Chinese medicine in 2 weeks;In four weeks, the drug or uv light treatment was used in the hormone.In 12 weeks, it was treated by methotrexate, cyclosporin A or antibiotic;In 24 weeks, he received avia or biologic agents.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Arriving rate of PASI-75; | — |
Secondary
| Measure | Time frame |
|---|---|
| Arriving rate of PASI-90;Adverse effects rate;Recurernce and rebound rate;First time to reach PASI-75;Drug dosage;Improvement of DLQI and Skindex 16;Patient drug compliance;Patient satisfaction; | — |
Countries
China
Contacts
Public ContactChuanjian Lu
Guangdong Provincial Hosptial of Chinese Medicine
Outcome results
None listed